Revolution Medicines Inc (RVMD) — Titan Protect Analysis

RVMD

Revolution Medicines Inc

Healthcare · ·

$149.23

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$32.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-27.29

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-76.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$183.00

+23% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 21 analysts covering this stock

About Revolution Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its

https://www.revmed.com

Country: United States Employees: 883 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.439

Excellent risk-adjusted returns

Kelly Fraction

0.1336

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.983

Returns exceed worst-case losses — strong risk profile

Annual Return

96.4%

Historical annualised return based on price data

Max Drawdown

-48.6%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.41

Moves slightly more than the broader market

52W High

$166.50

10% below the year high

52W Low

$34.00

339% above the year low

Avg Volume

3,005,830

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-7.11

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

29.15

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-606,370,880

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-1,371,700,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$263.00

Target Median

$183.00

Target Low

$151.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go